IDEXX Laboratories Inc (BSP:I1DX34)
R$ 485.25 0 (0%) Market Cap: 200.38 Bil Enterprise Value: 203.82 Bil PE Ratio: 50.45 PB Ratio: 27.53 GF Score: 99/100

IDEXX Laboratories Inc at Bank of America Merrill Lynch Animal Health Summit Transcript

Feb 24, 2020 / 03:55PM GMT
Michael Leonidovich Ryskin
BofA Merrill Lynch, Research Division - Associate

Here with us, we have Brian McKeon from -- CFO of IDEXX; and Tina Hunt, Head of VetLab for IDEXX Labs. We'll follow the same format, about 30 minutes of fireside chat and then some Q&A. Last session before lunch. So just hold on.

So maybe just to start, recap of where you are at the end of 2019, beginning of 2020, sort of what's your view of the market? How it's evolved? And sort of what are the big takeaways you have from us -- from the last year?

Brian P. McKeon
IDEXX Laboratories, Inc. - CFO, Executive VP & Treasurer

Yes. We had a very good 2019 as a company, very much aligned with our long-term performance goals. A key metric that we focus on is our CAG Diagnostics recurring revenue growth. So think of that as the recurring annuity revenues of the business, high margin, recurring revenue is about 75% of our total revenues. And normalized, they grew roughly 12% last year, 11% in the U.S., 13% internationally. Those metrics are all very well aligned with our long

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot